Ascidian Therapeutics
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
80 Guest St Fl 4, Boston, Massachusetts,...Website
www.ascidian-tx.comRevenue
$7.2 MillionIndustry
ZI Rank: 2
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
2
2
1
1
2
About Ascidian Therapeutics
Ascidian Therapeutics was founded to rewrite RNA by editing and replacing human exons, inspired by this example. In Ascidian's labs, RNA biology meets today's cutting-edge genomics, computational biology, and deep-sequencing technologies to create a new class of medicines that address the underlying causes of disease.Explore more
Ascidian Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ascidian Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Ascidian Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Ascidian Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Check if Ascidian Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Click to see if Ascidian Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Ascidian Therapeutics launches new products
Earning: See what the market has to say on Ascidian Therapeutics recently announced quarterly report
Check out if Ascidian Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Ascidian Therapeutics
Recommended Actions
Find VP level buyers at Ascidian Therapeutics
Find 3 more new buyers
Compare Similar Companies to Ascidian Therapeutics
Compare insights from companies similar to Ascidian Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Ascidian Therapeutics
$7.2M
11-50
Private
$50M
2020
JB
Jonathan BlancSenior Director, Corporate Development
Company Profile Activity
Activity Insights
Ascidian Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ascidian Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ascidian Therapeutics.
Ascidian Therapeutics financials insights
Gather financial insights about Ascidian Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$50M
Ascidian Therapeutics Tech Stack
A closer look at the technologies used by Ascidian Therapeutics
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Open Position
Open Position
Open Position
Open Position
Ascidian Therapeutics News & Media
Ascidian Therapeutics Appoints Dr. Murray A. Abramson as Chief Development Officer and Establishes Ophthalmology Clinical Advisory Board to Advance ACDN-01 for Treatment of Stargardt Disease
BOSTON, June 24, 2025 /PRNewswire/ -- Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced the appointment of Murray A. Abramson, MD, MPH, as Chief Development Officer. The company also announced its inaugural Ophthalmology...Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases
Ascidian to receive $42 million in initial payment, and up to $1.8 billion in research, clinical and commercial milestone payments, as well as commercial royalties Per-target agreement enables Ascidian to pursue additional internal and collaborative programs within neurology and other...Ascidian Therapeutics to Present Preclinical Data for RNA Exon Editor, ACDN-01, Supporting an Open IND for Phase 1/2 Clinical Testing at ASGCT 2024 Annual Meeting
Compelling translational insights underscore therapeutic potential of Ascidian's lead ACDN-01 program for people living with Stargardt disease and other ABCA4 retinopathies ACDN-01 awarded Rare Pediatric Disease Designation, following U.S. FDA IND clearance and Fast Track Designation...Ascidian Therapeutics Scores $40M in Series A Extension
BOSTON, MA, Ascidian Therapeutics, a biotechnology company, announced $40 million in Series A extension funding committed by Apple Tree Partners.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ascidian Therapeutics
Sign Up For FreeTo access detailed company insights
Ascidian Therapeutics was founded to rewrite RNA by editing and replacing human exons, inspired by this example. In Ascidian's labs, RNA biology meets today's cutting-edge genomics, computational biology, and deep-sequencing technologies to create a new class of medicines that address the underlying causes of disease.... Read More
